.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Federal Trade Commission
Accenture
Chubb
US Army
Teva
Julphar
McKesson
Express Scripts
Deloitte

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204447

« Back to Dashboard
NDA 204447 describes TRINTELLIX, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the TRINTELLIX profile page.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

Summary for NDA: 204447

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:5
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 204447

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRINTELLIX
vortioxetine hydrobromide
TABLET;ORAL 204447 NDA Takeda Pharmaceuticals America, Inc. 64764-550 64764-550-07 1 BOTTLE in 1 CARTON (64764-550-07) > 7 TABLET, FILM COATED in 1 BOTTLE
TRINTELLIX
vortioxetine hydrobromide
TABLET;ORAL 204447 NDA Takeda Pharmaceuticals America, Inc. 64764-550 64764-550-09 30 TABLET, FILM COATED in 1 BOTTLE (64764-550-09)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Sep 30, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 30, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Jan 9, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
Patent:► SubscribePatent Expiration:Oct 2, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Cerilliant
Healthtrust
Farmers Insurance
US Army
Citi
Chubb
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot